Could a transplant drug tame thyroid eye disease?
NCT ID NCT04936854
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This study compares sirolimus (an oral drug) to standard steroid infusions for treating active thyroid eye disease, a condition causing bulging eyes and discomfort. Researchers aim to see if sirolimus works better and causes fewer side effects. The trial involves 60 adults with moderate-to-severe disease and lasts 12 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sirolimus (oral tablet)
- What this could lead to
- If successful, sirolimus could offer a more effective and safer treatment option for active thyroid eye disease, reducing inflammation and eye bulging with fewer side effects than steroids.
- What could go wrong
- This is a small Phase 2 trial with only 60 participants, so results may not apply to everyone. Sirolimus may not work better than steroids and could have its own side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID ASSOCIATED OPHTHALMOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Ophthalmology Haukeland University Hospital
RECRUITINGBergen, Hordaland, 5021, Norway
More trials for these conditions
Other studies related to the condition(s) this trial covers.